{
  "id": 6146873,
  "title": "Novartis' Phase 3 pelacarsen study miss raises the stakes for Amgen, Lilly",
  "url": "https://urgent.news/2026/09/07/novartis-phase-3-pelacarsen-study-miss-raises-the-stakes-for-amgen",
  "topic": "culture",
  "section": "Culture",
  "published": "2026-09-07T14:48:28.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/novartis-phase-3-pelacarsen-study-miss-raises-the-stakes-for-amgen-lilly/"
  },
  "original_language": "en",
  "account": null,
  "summary": "After Novo Nordisk and AstraZeneca, Novartis is the third big pharma to suffer a major cardiovascular outcomes trial failure in the past two months. The Swiss pharma reported Friday that pelacarsen was no better than ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}